The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain

Journal of Virology

Volumn 84, Issue 3, 2010, Pages 1453-1463

  Tungteakkhun, Sandy S ^a   Filippova, Maria ^a   Fodor, Nadja ^a   Duerksen Hughes, Penelope J ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; ISOPROTEIN; PROCASPASE 8;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; E6 VIRUS GENE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SPLICEOSOME; VIRUS GENE;

APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; CASPASE 8; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; RNA SPLICING; TUMOR NECROSIS FACTOR-ALPHA;

HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 73949124438     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01331-09     Document Type: Article

References (60)

1. Alcami, A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50.
2. Be, X., Y. Hong, J. Wei, E. J. Androphy, J. J. Chen, and J. D. Baleja. 2001. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry 40:1293-1299.
3. Bedell, M. A., K. H. Jones, and L. A. Laimins. 1987. The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells. J. Virol. 61:3635-3640.
4. Belanger, C., A. Gravel, A. Tomoiu, M. E. Janelle, J. Gosselin, M. J. Tremblay, and L. Flamand. 2001. Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. J. Hum. Virol. 4:62-73.
5. Bertin, J., R. C. Armstrong, S. Ottilie, D. A. Martin, Y. Wang, S. Banks, G. H. Wang, T. G. Senkevich, E. S. Alnemri, B. Moss, M. J. Lenardo, K. J. Tomaselli, and J. I. Cohen. 1997. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 94:1172-1176.
6. Boccardo, E., and L. L. Villa. 2007. Viral origins of human cancer. Curr. Med. Chem. 14:2526-2539.
7. Brooks, H., B. Lebleu, and E. Vives. 2005. Tat peptide-mediated cellular delivery: back to basics. Adv. Drug Deliv. Rev. 57:559-577.
8. Butel, J. S. 2000. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21:405-426.
9. Carrington, P. E., C. Sandu, Y. Wei, J. M. Hill, G. Morisawa, T. Huang, E. Gavathiotis, Y. Wei, and M. H. Werner. 2006. The structure of FADD and its mode of interaction with procaspase-8. Mol. Cell 22:599-610.
10. Cereseto, A., Z. Berneman, I. Koralnik, J. Vaughn, G. Franchini, and M. E. Klotman. 1997. Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines. Leukemia 11:866-870.
11. Cooper, B., S. Schneider, J. Bohl, Y. Jiang, A. Beaudet, and S. Vande Pol. 2003. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology 306:87-99.
12. Cunnion, K. M. 1999. Tumor necrosis factor receptors encoded by poxviruses. Mol. Genet. Metab. 67:278-282.
13. de Turenne-Tessier, M., and T. Ooka. 2007. Post-translational modifications of Epstein Barr virus BARF1 oncogene-encoded polypeptide. J. Gen. Virol. 88:2656-2661.
14. Dowling, D., S. Nasr-Esfahani, C. H. Tan, K. O'Brien, J. L. Howard, D. A. Jans, D. F. Purcell, C. M. Stoltzfus, and S. Sonza. 2008. HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages. Retrovirology 5:18.
15. Elston, R. C., S. Napthine, and J. Doorbar. 1998. The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP. J. Gen. Virol. 79(Pt. 2):371-374.
16. Fawell, S., J. Seery, Y. Daikh, C. Moore, L. L. Chen, B. Pepinsky, and J. Barsoum. 1994. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U. S. A. 91:664-668.
17. Felsani, A., A. M. Mileo, and M. G. Paggi. 2006. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25:5277-5285.
18. Filippova, M., T. A. Brown-Bryan, C. A. Casiano, and P. J. Duerksen-Hughes. 2005. The human papillomavirus 16 E6 protein can either protect or further sensitize cells to TNF: effect of dose. Cell Death Differ. 12:1622-1635.
19. Filippova, M., V. A. Filippov, M. Kagoda, T. Garnett, N. Fodor, and P. J. Duerksen-Hughes. 2009. Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J. Virol. 83:210-227.
20. Filippova, M., M. M. Johnson, M. Bautista, V. Filippov, N. Fodor, S. S. Tungteakkhun, K. Williams, and P. J. Duerksen-Hughes. 2007. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 81:4116-4129.
21. Filippova, M., L. Parkhurst, and P. J. Duerksen-Hughes. 2004. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279:25729- 25744.
22. Filippova, M., H. Song, J. L. Connolly, T. S. Dermody, and P. J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277:21730-21739.
23. Gardiol, D., S. Galizzi, and L. Banks. 2002. Mutational analysis of the discs large tumour suppressor identifies domains responsible for human papillomavirus type 18 E6-mediated degradation. J. Gen. Virol. 83:283-289.
24. Garland, S. M. 2002. Human papillomavirus update with a particular focus on cervical disease. Pathology 34:213-224.
25. Garvey, T., J. Bertin, R. Siegel, M. Lenardo, and J. Cohen. 2002. The death effector domains (DEDs) of the molluscum contagiosum virus MC159 v-FLIP protein are not functionally interchangeable with each other or with the DEDs of caspase-8. Virology 300:217-225.
26. Gillison, M. L., W. M. Koch, R. B. Capone, M. Spafford, W. H. Westra, L. Wu, M. L. Zahurak, R. W. Daniel, M. Viglione, D. E. Symer, K. V. Shah, and D. Sidransky. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 92:709-720.
27. Hafner, N., C. Driesch, M. Gajda, L. Jansen, R. Kirchmayr, I. B. Runnebaum, and M. Durst. 2008. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27: 1610-1617.
28. Hoppe-Seyler, F., and K. Butz. 1995. Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. J. Mol. Med. 73:529-538.
29. Kaufmann, M., D. Bozic, C. Briand, J. L. Bodmer, O. Zerbe, A. Kohl, J. Tschopp, and M. G. Grutter. 2002. Identification of a basic surface area of the FADD death effector domain critical for apoptotic signaling. FEBS Lett. 527:250-254.
30. Lamb, R. A., and C. M. Horvath. 1991. Diversity of coding strategies in influenza viruses. Trends Genet. 7:261-266.
31. Langelier, Y., S. Bergeron, S. Chabaud, J. Lippens, C. Guilbault, A. M. Sasseville, S. Denis, D. D. Mosser, and B. Massie. 2002. The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation. J. Gen. Virol. 83:2779-2789.
32. Lee, C., and L. A. Laimins. 2004. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J. Virol. 78:12366-12377.
33. Liu, L., N. Bastien, and Y. Li. 2007. Intracellular processing, glycosylation, and cell surface expression of human metapneumovirus attachment glyco-protein. J. Virol. 81:13435-13443.
34. Liu, Y., and J. D. Baleja. 2008. Structure and function of the papillomavirus E6 protein and its interacting proteins. Front. Biosci. 13:121-134.
35. Liu, Y., Z. Liu, E. Androphy, J. Chen, and J. D. Baleja. 2004. Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry 43:7421-7431.
36. Lopes, V., L. S. Young, and P. G. Murray. 2003. Epstein-Barr virus-associated cancers: aetiology and treatment. Herpes 10:78-82.
37. Lutzelberger, M., L. S. Reinert, A. T. Das, B. Berkhout, and J. Kjems. 2006. A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability. J. Biol. Chem. 281:18644-18651.
38. Matsumoto, Y., S. Nakagawa, T. Yano, S. Takizawa, K. Nagasaka, K. Nakagawa, T. Minaguchi, O. Wada, H. Ooishi, K. Matsumoto, T. Yasugi, T. Kanda, J. M. Huibregtse, and Y. Taketani. 2006. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6. J. Med. Virol. 78:501-507.
39. Melton, J. L., and J. E. Rasmussen. 1991. Clinical manifestations of human papillomavirus infection in nongenital sites. Dermatol. Clin. 9:219-233.
40. Morris, J. D., A. L. Eddleston, and T. Crook. 1995. Viral infection and cancer. Lancet 346:754-758.
41. Motoyama, S., C. A. Ladines-Llave, S. L. Villanueva, and T. Maruo. 2004. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J. Med. Sci. 50:9-19.
42. Nomine, Y., M. Masson, S. Charbonnier, K. Zanier, T. Ristriani, F. Deryckere, A. P. Sibler, D. Desplancq, R. A. Atkinson, E. Weiss, G. Orfanoudakis, B. Kieffer, and G. Trave. 2006. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirusmediated pathogenesis. Mol. Cell 21:665-678.
43. Rohlfs, M., S. Winkenbach, S. Meyer, T. Rupp, and M. Durst. 1991. Viral transcription in human keratinocyte cell lines immortalized by human papillomavirus type-16. Virology 183:331-342.
44. Scheurer, M. E., G. Tortolero-Luna, and K. Adler-Storthz. 2005. Human papillomavirus infection: biology, epidemiology, and prevention. Int. J. Gynecol. Cancer 15:727-746.
45. Schiffman, M., P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907.
46. Schultz, D. R., and W. J. Harrington, Jr. 2003. Apoptosis: programmed cell death at a molecular level. Semin. Arthritis Rheum. 32:345-369.
47. Schwartz, J. J., and S. Zhang. 2000. Peptide-mediated cellular delivery. Curr. Opin. Mol. Ther. 2:162-167.
48. Shiratori, Y., S. Shiina, M. Imamura, N. Kato, F. Kanai, T. Okudaira, T. Teratani, G. Tohgo, N. Toda, M. Ohashi, et al. 1995. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 22:1027-1033.
49. Shisler, J. L., and B. Moss. 2001. Molluscum contagiosum virus inhibitors of apoptosis: the MC159 v-FLIP protein blocks Fas-induced activation of procaspases and degradation of the related MC160 protein. Virology 282:14-25.
50. Skaletskaya, A., L. M. Bartle, T. Chittenden, A. L. McCormick, E. S. Mocarski, and V. S. Goldmacher. 2001. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc. Natl. Acad. Sci. U. S. A. 98:7829-7834.
51. Talis, A. L., J. M. Huibregtse, and P. M. Howley. 1998. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273:6439-6445.
52. Tang, S., M. Tao, J. P. McCoy, Jr., and Z. M. Zheng. 2006. The E7 onco-protein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 80:4249-4263.
53. Tungteakkhun, S. S., and P. J. Duerksen-Hughes. 2008. Cellular binding partners of the human papillomavirus E6 protein. Arch. Virol. 153:397-408.
54. Tungteakkhun, S. S., M. Filippova, J. W. Neidigh, N. Fodor, and P. J. Duerksen-Hughes. 2008. The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. J. Virol. 82:9600-9614.
55. Wajant, H. 2002. The Fas signaling pathway: more than a paradigm. Science 296:1635-1636.
56. Zhou, Q., S. Snipas, K. Orth, M. Muzio, V. M. Dixit, and G. S. Salvesen. 1997. Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J. Biol. Chem. 272:7797-7800.
57. Ziff, E. B. 1985. Splicing in adenovirus and other animal viruses. Int. Rev. Cytol. 93:327-358.
58. Zimmermann, K. C., C. Bonzon, and D. R. Green. 2001. The machinery of programmed cell death. Pharmacol. Ther. 92:57-70.
59. Zimmermann, K. C., and D. R. Green. 2001. How cells die: apoptosis pathways. J. Allergy Clin. Immunol. 108:S99-S103.
60. zur Hausen, H. 1991. Viruses in human cancers. Science 254:1167-1173.